Damora Therapeutics, Inc. Ordinary Shares (DMRA) Stock Price

DMRAStock
$29.00
Market Cap$1.79B
P/E
PEG Ratio
Div yield
Beta-4.54

DMRA Share Price Chart

Favorite Metrics

Price vs S&P 500 (4W)-0.00%
VGM Score56.57

DMRA Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.37-$0.39-5.41%(-$0.02)
Q3 2025-$2.36

DMRA Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.25
4.31
4.27
4.31

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
DMRADamora Therapeutics, Inc. Ordinary Shares
C$29.00
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Damora Therapeutics, Inc. Ordinary Shares

Damora Therapeutics develops biologics for calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant unmet medical need for disease-modifying treatments. The company's pipeline includes DMR-001, DMR-002, DMR-003, and GB3226, designed to provide broad mutation coverage in hematologic disorders.